Category: Health Science
-
![Predictmedix (PMED.C) killing it on new COVID-19 screening tech]()
Predictmedix (PMED.C) killing it on new COVID-19 screening tech
I love it when a plan comes together. Predictmedix (PMED.C) continued to launch itself upward this week, jumping from $0.72 to $0.98 in just days, on the back of news it’s being used by a large events company, and financials that show a very short road to profitability. For those that haven’t been paying attention…
-
Biotech: Who Will Survive When The COVID-19 Hype Ends?
Over the last couple of months, companies have found a way to muster up an effort to align their objectives with helping society recover from this global pandemic – COVID-19. The result: share prices have soared like never before. The line up of biotech companies trying to come up with COVID-19 vaccines or cures is…
-
Everything is up: Eat, drink, be merry… for tomorrow we die
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in order to save us from economic collapse, the government printed trillions of dollars and just fired it all into the markets out of a bazooka, only to establish a decades-long…
-
![Predictmedix (PMED.C) inks deal to install COVID-19 Mass Screening Tech]()
Predictmedix (PMED.C) inks deal to install COVID-19 Mass Screening Tech
“Predictmedix’ best-in-class screening technology pairs perfectly with our ability to custom-fabricate quickly and efficiently,” states Jonathan Auger, CEO of Juiceworks Exhibits
-
![PredictMedix: Pharma Monopoly Meets Tech Growth]()
PredictMedix: Pharma Monopoly Meets Tech Growth
Here’s a simple and effective investment strategy: invest in companies that sell products with growing inelastic demand.
-
Revive Therapeutics’ (RVV.C) product pipeline is flowing freakishly fast
Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19)
-
Predictmedix (PMED.C) bursts out of the starting blocks with 3 big alliances
Two weeks ago, Predictmedix filed a Patent Application in the U.S. for its AI-driven rapid screening system for infectious diseases.
-
Chartwell Retirement Residences (CSH.UN.T), Extendicare (EXE.T), Sienna Senior Living (SIA.T): are Canadian parents safe in senior care homes?
Growing old is a messy business. Institutional care for seniors will never provide perfect solutions. The challenge is not to make a perfect system, but to mitigate the health risks of long term care, intelligently and ethically.
-
Revive Therapeutics (RVV.C): Kicked around, called a fraud, gets FDA approval of Phase 3 COVID-19 trials
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he put out news claiming his little pharma company, which had built a reputation for chasing aggressively into new pharmaceutical fields, had found some IP that might be useful in the…
-
Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts…
